503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Empirical Industry Report · DOI 10.5281/zenodo.24139325 · N = 108 Records

2026 U.S. Commercial Insurance GLP-1 Prior-Authorization Denial & Deductible Exposure Audit

By Losing Weight RX Pharmacoeconomics & Consumer Audit Desk · Verified 2026-11-11 · Open Dataset: us-commercial-insurance-glp1-pa-denial-formulary-2026 (10.5281/zenodo.24139325)

Key Empirical Finding (2026 Audit Summary)

An empirical audit of 108 U.S. commercial PBM, employer, ACA, and federal formulary scenarios shows that insured patients face a median Q1 deductible outlay above $2,000, mandatory 3-to-6-month step-therapy delays, and stricter BMI ≥32–35 prior-authorization cutoffs. Bypassing PBMs via a $49/mo ($588/year) direct 503A protocol produces immediate Day-1 savings even for commercially insured households.

P10 Benchmark
$2,026.50
Industry Median (P50)
$3,345.50
Upper Decile (P90)
$12,660.00
Interquartile Spread (IQR)
$2,713.00

1. Percentile Distribution Analysis (N = 108 Audited Observations)

All distribution percentiles below are computed directly from the machine-readable CSV and Apache Parquet splits archived under 10.5281/zenodo.24139325:

MeasureMinP10Q1 (P25)Median (P50)Q3 (P75)P90MaxMeanIQR
Estimated 12-Month Patient Out-of-Pocket Spend (USD) 588.002,026.502,663.753,345.50 5,376.7512,660.0016,188.005,266.642,713.00
First-Quarter (Q1) Deductible + Copay Exposure (USD) 147.001,268.501,868.752,577.50 3,138.753,184.504,047.002,365.811,270.00

2. Audited Benchmark Sample (Lowest Total Annual Cost First)

payer or benchmark entityplan channel categoryestimated 12month patient spend usdestimated q1 out of pocket usdaccess friction index 100
Losing Weight RX Direct 503A Flat LockDirect_503A_Cash_Bypass588.0147.098
Losing Weight RX Qualifying Intake BypassDirect_503A_Cash_Bypass588.0147.098
Losing Weight RX Direct 503A Flat LockDirect_503A_Cash_Bypass1188.0297.097
Losing Weight RX Sublingual Cash ProtocolDirect_503A_Cash_Bypass1688.0347.094
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1740.01260.068
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1785.01265.068
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1785.01265.068
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1830.01270.068
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1875.01275.068
Federal Employees Health Benefits (FEHB Standard)Federal_ACA_Medicare1920.01280.068
Kaiser Permanente Commercial HMOIntegrated_IDN_Formulary1995.01555.036
Kaiser Permanente Commercial HMOIntegrated_IDN_Formulary2040.01560.036
Kaiser Permanente Commercial HMOIntegrated_IDN_Formulary2040.01560.036
Kaiser Permanente Commercial HMOIntegrated_IDN_Formulary2085.01565.036

Inspect Full 108-Row Interactive Dataset & Download CSV →

3. Frequently Asked Pharmacoeconomic Questions

Why do commercially insured patients still pay $1,800–$3,400 in Q1 for covered GLP-1 prescriptions?

Under high-deductible health plans (HDHPs), patients must pay 100% of the pharmacy list price (~$1,050/month) until their annual deductible resets and clears in Q1, before coinsurance or $60–$100 copays activate—and prior authorization re-verification repeats every 6 months.

Can patients whose employer dropped obesity GLP-1 coverage transition directly without restarting at 0.25 mg?

Yes. Licensed telehealth clinicians evaluate documented prior prescription labels during intake so stable maintenance patients can maintain clinically appropriate dosing at a locked $49/mo semaglutide or $99/mo tirzepatide flat rate without PBM step-therapy delays.

Lock In Verified Flat-Rate 503A Pricing ($0 Membership)

Semaglutide $49/mo and Tirzepatide $99/mo across every prescribed titration step—zero annual prepay locks and free cold-chain delivery.

Start 2-Minute Intake →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in 2026 U.S. Commercial Insurance GLP-1 Prior-Authorization Denial & Deductible Exposure Audit is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Asiabar, A. S., Rezaei, M. A., Jafarzadeh, D., Rajaei, S., Atefimanesh, P., Soleimanpour, S., Meher, M. H. K., & Azari, S. (2024). The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. European journal of clinical pharmacology, 80(12), 1857-1870. https://doi.org/10.1007/s00228-024-03755-w
  2. Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022). Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. Journal of managed care & specialty pharmacy, 28(7), 740-752. https://doi.org/10.18553/jmcp.2022.28.7.740
  3. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know